Effectiveness of 8-week Treatment with Glecaprevir/Pibrentasvir in Treatment-naïve or -experienced HCV Patients: Results from an Observational Retrospective Study in Real-life Settings (ODYSSEY)
Authors:
- Anca TrifanAnca Trifan
- Carol StanciuCSCarol Stanciu
- Adrian Streinu-CercelASAdrian Streinu-Cercel
- Augustina CulinescuACAugustina Culinescu
- Liliana BaroiuLBLiliana Baroiu
- Eugen DumitruEDEugen Dumitru
- Cristina PojogaCPCristina Pojoga
- Ciprian BriscCBCiprian Brisc
- Mihaela Mihaela BriscMBMihaela Mihaela Brisc
- Dan Ionut GheoneaDan Ionut Gheonea
- Dan Nicolae FlorescuDFDan Nicolae Florescu
- Corina Silvia PopCorina Silvia Pop
Open Access
- 28 December 2024
- journal article
- research article
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 33 (4) , 503-509
Abstract
Background and Aims: Pan-genotypic ribavirin-free oral direct-acting antivirals, including the glecaprevir/pibrentasvir combination, are recommended for the treatment of most patients with chronic hepatitis C virus (HCV) infection. In Romania, the HCV-infected patient population receiving glecaprevir/pibrentasvir is not well characterized and data on treatment effectiveness is lacking. The ODYSSEY study aimed to provide insights into the characteristics and treatment outcomes of HCV-infected Romanian patients receiving 8-week therapy with glecaprevir/pibrentasvir. Methods: This observational, retrospective medical chart review study was based on a Patient Support Program for HCV-infected patients (HCV-PSP) attending clinical practices in Romania and initiating glecaprevir/pibrentasvir between 01 February 2022 and 11 July 2023. Patients ≥18 years of age with compensated liver disease F0-F4 fibrosis grade treatment-naïve or F0-F3 fibrosis grade treatment-experienced on previous interferon-based regimens from the HCV-PSP were included in the ODYSSEY study. Patients received glecaprevir/pibrentasvir for at least 8 weeks. Sustained virological response (SVR) was assessed at 12 weeks after the 8-week treatment (SVR12). Analyses were conducted on the core population (CP) and the CP with sufficient follow-up data (CPSFU). Results: The CP and CPSFU included 2,240 and 2,165 patients, respectively. In both populations, most patients were female (≥67.57%), aged >50 years (≥73.62%), and treatment-naïve (≥96.47%). F4 fibrosis was reported in 19% of patients. Hypertension was the most common relevant comorbidity, reported for 21% of patients; comorbidity rates increased with age. Overall SVR12 rates were 96.1% [95% confidence interval (CI): 95.2-96.8%) and 99.3% (95%CI: 98.9–99.6) in the CP and CPSFU, respectively. When stratified by gender, age category, comorbidities or fibrosis grade, SVR12 rates were >92% in the CP [except for the subgroups of patients with chronic kidney disease (87.5%) and depressive-/anxiety disorders (86.2%)] and ≥97.0% in the CPSFU. SVR12 rates were higher in female patients. In an exploratory analysis, in the CPSFU, the presence of diabetes mellitus [odds ratio (OR)=3.840; 95%CI: 1.093–13.495] and cardiovascular diseases (OR=7.904; 95%CI: 1.719-36.346) were associated with an increased probability to detect HCV RNA at 12 weeks post-treatment. Conclusions: The 8-week treatment with glecaprevir/pibrentasvir resulted in high SVR12 rates for multiple HCV-infected patient profiles encountered in real-life settings in Romania.Keywords
This publication has 28 references indexed in Scilit:
- Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and CirrhosisAdvances in Therapy, 2024
- Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesisThe Lancet Regional Health - Europe, 2023
- Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV PatientsInfectious Diseases and Therapy, 2023
- Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registryHepatology International, 2023
- Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis CJournal of the Formosan Medical Association, 2022
- Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST StudyAdvances in Therapy, 2022
- EASL recommendations on treatment of hepatitis C: Final update of the series☆Journal of Hepatology, 2020
- Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysisJournal of Hepatology, 2020
- HepCare Europe—A service innovation project. HepCheck: Characteristics of the patient population with active infection as defined by HCV RNAInternational Journal of Infectious Diseases, 2020
- Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1–6 infection: A systematic review and meta-analysisInternational Journal of Antimicrobial Agents, 2019